Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

被引：0
|
作者：
Weeding, Emma [1 ]
Fava, Andrea [1 ]
Mohan, Chandra [2 ]
Goldman, Daniel
Petri, Michelle [3 ]
机构：
[1] Johns Hopkins Univ Hosp, Baltimore, MD USA
[2] Univ Houston, Houston, TX USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1737
引用
收藏
页码：3619 / 3621
页数：3
相关论文
共 50 条
  • [31] URINARY SOLUBLE CD163 AND ACTIVE CRESCENTIC GLOMERULONEPHRITIS IN ANCA-ASSOCIATED VASCULITIS
    Aendekerk, Joop
    Timmermans, Sjoerd
    Potjewijd, Judith
    Heeringa, Peter
    van Paassen, Pieter
    RHEUMATOLOGY, 2019, 58
  • [32] Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss
    Xie, Peilin
    Yao, Bilian
    Huang, Dao
    Chen, Yongyan
    Gong, Qiming
    Zhang, Xinxin
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (06) : 1059 - 1067
  • [33] Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment
    Gupta, Ranjan
    Yadav, Akhilesh
    Aggarwal, Amita
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] Belimumab as add-on treatment in lupus nephritis (summary of the BLISS-LN trial)
    Hadjiski, D.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (03): : 283 - 284
  • [35] Urine proteomic insights from the belimumab in lupus nephritis trial
    Weeding, Emma
    Fava, Andrea
    Mohan, Chandra
    Magder, Laurence
    Goldman, Daniel
    Petri, Michelle
    LUPUS SCIENCE & MEDICINE, 2022, 9 (01):
  • [36] Soluble CD163 Is Associated With CD163 mRNA Expression in Adipose Tissue and With Insulin Sensitivity in Steady-State Condition but Not in Response to Calorie Restriction
    Kracmerova, Jana
    Rossmeislova, Lenka
    Kovacova, Zuzana
    Klimcakova, Eva
    Polak, Jan
    Tencerova, Michaela
    Malisova, Lucia
    Stich, Vladimir
    Langin, Dominique
    Siklova, Michaela
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (03): : E528 - E535
  • [37] Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus
    Nishino, A.
    Katsumata, Y.
    Kawasumi, H.
    Hirahara, S.
    Kawaguchi, Y.
    Yamanaka, H.
    LUPUS, 2019, 28 (08) : 986 - 994
  • [38] Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
    Frieri, Marianne
    Heuser, William
    Bliss, Joshua
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2015, 6 (02) : 71 - 76
  • [39] Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
    Atisha-Fregoso, Yemil
    Malkiel, Susan
    Harris, Kristina M.
    Byron, Margie
    Ding, Linna
    Kanaparthi, Sai
    Barry, William T.
    Gao, Wendy
    Ryker, Kristin
    Tosta, Patti
    Askanase, Anca D.
    Boackle, Susan A.
    Chatham, W. Winn
    Kamen, Diane L.
    Karp, David R.
    Kirou, Kyriakos A.
    Sam Lim, S.
    Marder, Bradley
    McMahon, Maureen
    Parikh, Samir V.
    Pendergraft, William F., III
    Podoll, Amber S.
    Saxena, Amit
    Wofsy, David
    Diamond, Betty
    Smilek, Dawn E.
    Aranow, Cynthia
    Dall'Era, Maria
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (01) : 121 - 131
  • [40] Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
    Furie, Richard
    Rovin, Brad H.
    Houssiau, Frederic
    Malvar, Ana
    Teng, Y. K. Onno
    Contreras, Gabriel
    Amoura, Zahir
    Yu, Xueqing
    Mok, Chi-Chiu
    Santiago, Mittermayer B.
    Saxena, Amit
    Green, Yulia
    Ji, Beulah
    Kleoudis, Christi
    Burriss, Susan W.
    Barnett, Carly
    Roth, David A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12): : 1117 - 1128
12345